Modulating Type 1 Interferon May Expand Treatment Options for COVID-19
July 28, 2023
Media Contacts
Lisa Newbern
ATLANTA – In their continuing work to limit the impact of COVID-19, Emory University researchers have, for the first time in nonhuman primates, studied how modulating the signaling of type 1 Interferon (IFN-I), one of the body's initial defenses against infection, impacts SARS-CoV-2 viral replication and disease progression. The findings, which are reported in Science Immunology, demonstrate a critical role of IFN-I in SARS-CoV-2 infection and could help in the development of new treatment strategies for COVID-19.
Senior author Mirko Paiardini, PhD, led the study that showed while early antiviral IFN-I responses are crucial for restraining SARS-CoV-2 replication, excessive IFN-I signaling contributes to hyperinflammation in rhesus macaques. This animal species is a critical model for studying mild/moderate COVID-19.
"Our finding reinforces how critical it is to prevent or quickly treat excessive inflammation, which is considered the main cause of severe COVID-19," Paiardini says. He is division chief of Microbiology and Immunology at the Emory National Primate Research Center (EPC), professor of Pathology and Laboratory Medicine at Emory University School of Medicine and at the Emory Vaccine Center, co-director at the Emory Center for AIDS Research and the lead principal investigator of the ERASE-HIV Martin Delaney Collaboratory for HIV Cure Research.
Working in close collaboration with Paiardini on this study were Steve Bosinger, PhD, co-first authors Elise Viox, Timothy Hoang, PhD, and Amit Upadhyay, PhD, and R. Paul Johnson, MD. Bosinger is director of the EPC Nonhuman Primate Genomics Core and assistant professor in the Emory School of Medicine Department of Pathology & Lab Medicine. Johnson is director of the EPC.
The researchers used a mutated version of interferon (IFNmod) to modulate IFN-I signaling in rhesus macaques before and during acute SARS-CoV-2 infection. Their results showed IFNmod treatment weakened antiviral and inflammatory gene expression and led to lower levels of inflammatory cytokines, substances that have an effect on other cells, in the lower airways and reduced lung pathology. "We were also surprised to find IFNmod treatment had a profound effect on SARS-CoV-2 viral loads, with a 3,000-fold reduction in viral loads in the lower airways of treated animals," says Viox.
In addition to Emory, the research team includes researchers from the Institute of Molecular Virology at Ulm University Medical Center in Germany, Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, Weizmann Institute of Science in Israel, , University of Washington School of Medicine, Washington National Primate Research Center (WaNPRC), Access to Advanced Health Institute in Seattle, Vaccine and Gene Therapy Institute and Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University, Tulane National Primate Research Center, and Tulane School of Medicine.
The research team dedicates this scientific publication in loving memory to co-first author Timothy Hoang, PhD, whose commitment to this project and to scientific discovery were crucial in propelling this study forward. Hoang is remembered for his intelligence, drive and love for science, and all of the lives he touched during his short but impactful career.
The research reported in this release is supported in part by the National Institutes of Health, including Office of the Director, Emory University, Fast Grants, a private foundation, the German Research Foundation and the German Federal Ministry for Research and Education.
The most recent annual awards and supplements, including direct and indirect costs, for the U.S.-based grants are listed below. The amounts listed are for the full grants. Only a portion of each grant supported the research reported in this news release.
- NIH/Office of the Director
- P510D011132-60S4 (to EPOC), $10,751,414/1 year
- P51 OD010425 (WaNPRC), $12,968,296/1 year
- P51 OD011092 (ONPRC), $13,153,537/1 year
- Other NIH
- COVTEN/ACTIV (to Paiardini and Johnson), $784,482 and $1,242,793
- 1RO1 HL140223 (to RDL)
- Yr1: $453,348,
- Yr2: $449,667
- Yr3: 445,767, Yr3 supplement: $78,250
- Yr4: $443,520
- Yr5: 436,500
- P30 AI050409 to the Emory Center for AIDS Research Systems Immunology Core (Johnson)
- Yr21: $4,129,580
- Yr22: $3,951,309
- Yr23: $3,661,998
- Yr24: $5,133,660
- Yr25: $2,131,578
- S10OD026799 (to Bosinger), $985,030
- Emory MP3 Grant (to Paiardini, $150,000
- Fast Grants #2144 (to Paiardini, $150,000
- Pitts Foundation (to Paiardini), $180,000
Dedicated to discovering causes, preventions, treatments and cures, the Emory National Primate Research Center (EPC), part of Emory University's Robert W. Woodruff Health Sciences Center, is fighting diseases and improving human health and lives worldwide. The center, one of only seven NPRCs the National Institutes of Health (NIH) funds, is supported by more than $100 million in research funding (all sources, fiscal year 2022). EPC researchers are making landmark discoveries in: microbiology and immunology; neurologic diseases; neuropharmacology; behavioral, cognitive and developmental neuroscience; and psychiatric disorders. Since 1984, the center has been fully accredited by the AAALAC International, regarded as the gold seal of approval for laboratory animal care.